<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Empagliflozin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Empagliflozin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Empagliflozin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="96484" href="/d/html/96484.html" rel="external">see "Empagliflozin: Drug information"</a> and <a class="drug drug_patient" data-topicid="96542" href="/d/html/96542.html" rel="external">see "Empagliflozin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F25590209"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Jardiance</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871786"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Jardiance</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F58523179"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</span>;</li>
<li>
<span class="list-set-name">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F58523211"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical consideration</b>
<b>s: </b>Correct hypovolemia, if present, prior to initiating treatment. May require a gradual dose reduction of insulin and/or insulin secretagogues (eg, sulfonylureas) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7253bb59-b685-4f43-aa48-4aa83f602807">Diabetes mellitus, type 2; adjunct to diet and exercise</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2; adjunct to diet and exercise:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Oral: Initial: 10 mg once daily; may increase to 25 mg once daily if tolerated and glycemic targets not achieved after an adequate trial (in pediatric trial, doses were assessed after 12 to 14 weeks duration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36738751','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36738751','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F58523230"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: There are no pediatric-specific recommendations in the manufacturer's labeling; in pediatric trials, patients with eGFR &lt;60 mL/minute/1.73 m<sup>2</sup> were excluded.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use not recommended. <b>Note:</b> In pediatric trials, patients with eGFR &lt;60 mL/minute/1.73 m<sup>2</sup> were excluded.</p></div>
<div class="block dohp drugH1Div" id="F58523234"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥10 years and Adolescents: Oral: No dosage adjustment necessary. Systemic exposure is increased in hepatic impairment, but changes are not considered clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23859534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23859534'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F26251410"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="96484" href="/d/html/96484.html" rel="external">see "Empagliflozin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Correct hypovolemia, if present, prior to initiating treatment. Patients may require a gradual dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to reduce the risk of hypoglycemia when used in combination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47e458e4-daa4-401c-b15c-19b6e3e7d4a7">Chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used to reduce the risk of chronic kidney disease progression in patients with persistent proteinuria (eg, urine albumin-to-creatinine ratio [UACR] &gt;300 mg/g) despite receiving optimized treatment with (or having an intolerance to) an angiotensin-converting enzyme inhibitor or angiotensin -receptor blocker. Benefits were consistently demonstrated in patients with or without type 2 diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36331190','lexi-content-ref-Rosenberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36331190','lexi-content-ref-Rosenberg.1'])">Ref</a></span>). For patients with type 2 diabetes, some experts also use this regimen with lower levels of urine albumin excretion (eg, UACR ≤300 mg/g); benefits and harms may be more closely balanced due to smaller absolute benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36507634','lexi-content-ref-31495651']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36507634','lexi-content-ref-31495651'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36331190','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36331190','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> those who cannot take metformin. May be preferred in patients with atherosclerotic cardiovascular disease (ASCVD), heart failure, or diabetic kidney disease given demonstrated cardiovascular and renal benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-DeSantis.1','lexi-content-ref-26378978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-DeSantis.1','lexi-content-ref-26378978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyperglycemia: </i>
<b>Oral:</b> Initial: 10 mg once daily; may increase to 25 mg once daily after 4 to 12 weeks if needed to achieve glycemic goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeSantis.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeSantis.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atherosclerotic cardiovascular disease:</i>
<b>Note:</b> In patients with type 2 diabetes mellitus and established ASCVD, empagliflozin is approved to reduce the risk of major adverse cardiovascular events and cardiovascular death and has been shown (off label) to reduce the risk of heart failure hospitalization in these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30424892','lexi-content-ref-26378978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30424892','lexi-content-ref-26378978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 or 25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30424892','lexi-content-ref-26378978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30424892','lexi-content-ref-26378978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diabetic kidney disease (off-label use): </i>
<b>Oral:</b> 10 mg once daily in patients with urinary albumin excretion &gt;300 mg/day; it is unknown if higher doses result in better kidney protection.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Some experts also use this regimen in patients <b>without </b>severely increased albuminuria (eg, urinary albumin excretion ≤300 mg/day); benefits and harms may be more closely balanced due to smaller absolute benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36331190','lexi-content-ref-31495651','lexi-content-ref-Perkovic.1','lexi-content-ref-27299675','lexi-content-ref-28904068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36331190','lexi-content-ref-31495651','lexi-content-ref-Perkovic.1','lexi-content-ref-27299675','lexi-content-ref-28904068'])">Ref</a></span>). Because SGLT2 inhibitors have less glycemic benefit as eGFR declines, another agent may be needed to achieve glycemic goals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart failure:</i>
<b>Oral:</b> 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34449189','lexi-content-ref-32865377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34449189','lexi-content-ref-32865377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In patients with type 2 diabetes mellitus and heart failure, empagliflozin has been shown to reduce the risk of hospitalization for heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34449189','lexi-content-ref-32865377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34449189','lexi-content-ref-32865377'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Should be considered for use in combination with other evidence-based medical therapies as part of an optimal medical regimen for heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-34449189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-34449189'])">Ref</a></span>). Benefits were consistently demonstrated in patients with or without type 2 diabetes, regardless of ejection fraction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34449189','lexi-content-ref-32865377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34449189','lexi-content-ref-32865377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991166"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27299675','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27299675','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Chronic kidney disease (off-label use):</b> No dosage adjustment necessary for eGFR ≥20 mL/minute/1.73 m<sup>2</sup>; therapy was not initiated in patients with an eGFR &lt;20 mL/minute/1.73 m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36331190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36331190'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:8em;">The US manufacturer does not recommend use for glycemic control; however, in patients previously established on empagliflozin, some experts continue use off label at a dose of 10 mg once daily as a treatment for diabetic kidney disease; renal and heart failure benefits have been shown in patients with an eGFR ≥20 mL/minute/1.73 m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34449189','lexi-content-ref-36331190','lexi-content-ref-32865377','lexi-content-ref-Perkovic.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34449189','lexi-content-ref-36331190','lexi-content-ref-32865377','lexi-content-ref-Perkovic.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Heart failure: </b>Benefits of 10 mg once daily have been shown in patients with an eGFR ≥20 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34449189','lexi-content-ref-32865377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34449189','lexi-content-ref-32865377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Unlikely to be significantly dialyzable (highly protein bound): Avoid use (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (highly protein bound): Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988539"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Systemic exposure is increased in hepatic impairment, but changes are not considered clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23859534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23859534'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54836149"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>acute kidney injury </b>(AKI) have been reported in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors (specifically canagliflozin and dapagliflozin), including cases that have required hospitalization and dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2016'])">Ref</a></span>). In addition, cases of AKI (including <b>acute interstitial nephritis</b> [Ryan 2020]), acute renal failure, and <b>increased serum creatinine</b> have been noted with some patients receiving empagliflozin, although less often than what was seen with placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27299675','lexi-content-ref-26378978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27299675','lexi-content-ref-26378978'])">Ref</a></span>); further analysis of this showed an early <b>decreased estimated GFR</b> (eGFR) (empagliflozin 10 mg: -0.62 mL/minute/1.73 m<sup>2</sup> per week; empagliflozin 25 mg: -0.82 mL/minute/1.73 m<sup>2</sup> per week; placebo: +0.01 mL/minute/1.73 m<sup>2</sup> per week [p&lt;0.001 for both comparisons with placebo]) which tended to stabilize after ~4 weeks and an overall reduction in adverse kidney outcomes (eg, initiation of renal replacement therapy, doubling of serum creatinine with eGFR ≤45 mL/minute/1.73 m<sup>2</sup>, progression to macroalbuminuria, death from kidney disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27299675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27299675'])">Ref</a></span>). As evidence mounts for the positive effects of these agents on long-term kidney outcomes and a possible reduction in the incidence of AKI with empagliflozin specifically, clinicians will need to weigh the potential risk of AKI with the overall benefit of these agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30939483','lexi-content-ref-31050116','lexi-content-ref-28605608','lexi-content-ref-31495651','lexi-content-ref-28240446','lexi-content-ref-27299675','lexi-content-ref-30415602','lexi-content-ref-26378978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30939483','lexi-content-ref-31050116','lexi-content-ref-28605608','lexi-content-ref-31495651','lexi-content-ref-28240446','lexi-content-ref-27299675','lexi-content-ref-30415602','lexi-content-ref-26378978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. SGLT2 inhibition causes increased excretion of glucose and sodium, thereby resulting in an osmotic diuresis; the subsequent hyperosmolarity and volume contraction may increase the risk of AKI. Glucose in the urine may be reabsorbed by glucose transporters in exchange for uric acid, resulting in uricosuria and associated crystal-dependent and -independent damage. Lastly, SGLT2 inhibition results in increased fructose generation; the metabolism of fructose may lead to increased uric acid, oxidative stress, and the release of chemokines, thus causing local tubular injury and inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31050116','lexi-content-ref-27847389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31050116','lexi-content-ref-27847389'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">On the other hand, empagliflozin may confer some protection against AKI. Proposed mechanisms based on animal studies regarding the beneficial effects of SGLT2 inhibition on AKI include improved kidney cortical oxygen tension, tubular cell integrity, and tubular albumin reabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26041448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26041448'])">Ref</a></span>); in addition, improved cardiac function may be related to improved kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30939483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30939483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. With regard to decreases in eGFR, in the EMPA-REG OUTCOME study, administration of empagliflozin caused early decline in eGFR which tended to stabilize after ~4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27299675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27299675'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting risk factors for AKI (eg, hypovolemia, chronic kidney insufficiency, heart failure, use of concomitant medications [eg, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increased incidence of bone fractures has been observed with other sodium-glucose cotransporter 2 (SGLT2) inhibitors in some clinical trials. However, meta-analyses of trial data for empagliflozin have not demonstrated increased risk of fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28440590','lexi-content-ref-28240446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28440590','lexi-content-ref-28240446'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, including <b>angioedema</b>, <b>asthma</b>, <b>urticaria,</b> and <b>skin rash</b>, have been reported in patients receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29949041','lexi-content-ref-EMT.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29949041','lexi-content-ref-EMT.2017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Multiple potential mechanisms</p>
<p style="text-indent:-2em;margin-left:6em;">Non–dose-related; immunologic: IgE-mediated or direct mast cell stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Dose-related; related to the pharmacologic action: Elevated levels of bradykinin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9734886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9734886'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; generally occurs hours to days after treatment initiation. In a review of postmarketing data, time to onset was within 1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMT.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMT.2017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior serious hypersensitivity reaction to empagliflozin</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity:<b></b>Although other SGLT2 have also been associated with hypersensitivity reactions, there are no reports of cross-reactions between these agents</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension/volume depletion</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium-glucose cotransporter 2 (SGLT2) inhibitors may cause events consistent with <b>hypovolemia</b>, including symptomatic hypotension, syncope, and dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28631216','lexi-content-ref-25271206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28631216','lexi-content-ref-25271206'])">Ref</a></span>). Overall, a reduction in both systolic and diastolic blood pressure (-4 to -6/-1 to -2 mm Hg) has been documented for SGLT2 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-28546454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-28546454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Inhibition of SGLT2 causes an increase in the excretion of glucose and sodium, thereby resulting in an osmotic diuresis and intravascular volume contraction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28546454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28546454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; timing is impacted by volume status (eg, reduced oral intake, fluid losses) and concomitant use of medications known to impact volume status or blood pressure (eg, diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (ie, eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of antihypertensives (eg, diuretics, ACE inhibitors, ARBs)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting low systolic blood pressure</p>
<p style="text-indent:-2em;margin-left:6em;">• Reduced oral intake or increased fluid losses</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including empagliflozin, have been associated with an increased risk of <b>genitourinary fungal infection</b> (eg, vulvovaginal mycotic infection, vulvovaginal candidiasis, vulvovaginitis, candida balanitis, balanoposthitis) and, to a lesser extent, <b>urinary tract infections</b>, including severe cases of <b>urinary tract infection with sepsis</b> and <b>pyelonephritis</b> requiring hospitalization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30207042','lexi-content-ref-27085585','lexi-content-ref-27876693','lexi-content-ref-27862830']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30207042','lexi-content-ref-27085585','lexi-content-ref-27876693','lexi-content-ref-27862830'])">Ref</a></span>). These events are generally mild in intensity, respond to treatment, and do not lead to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26982554','lexi-content-ref-23963895']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26982554','lexi-content-ref-23963895'])">Ref</a></span>). Additionally, rare but serious and potentially fatal cases of <b>necrotizing fasciitis (perineum)</b> (ie, Fournier gangrene) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060053','lexi-content-ref-FDA.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060053','lexi-content-ref-FDA.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Patients with diabetes are more prone to urinary tract and genital infections, potentially due to glucosuria-induced bacterial growth, increased adherence of bacteria to the uroepithelium, and altered immune function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24529566','lexi-content-ref-28888425','lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24529566','lexi-content-ref-28888425','lexi-content-ref-23748505'])">Ref</a></span>). Because SGLT2 inhibitors increase urinary excretion of glucose, it has been hypothesized that these agents further increase the risk of these infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24529566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24529566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; available literature suggests that the increased risk of genital infection may be apparent within the first month of SGLT2 inhibitor therapy and remain elevated throughout the course of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30207042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30207042'])">Ref</a></span>); Fournier gangrene may have an average onset of 9 months (range: 5 days to 49 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060053'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes and/or uncontrolled hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28888425','lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28888425','lexi-content-ref-23748505'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of these types of infections</p>
<p style="text-indent:-2em;margin-left:6em;">• Uncircumcised males (increased risk for genital infections) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23748505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23748505'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ketoacidosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>ketoacidosis </b>have been reported in patients with type 1 and type 2 diabetes mellitus receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors, including empagliflozin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2015','lexi-content-ref-30287422','lexi-content-ref-26378978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2015','lexi-content-ref-30287422','lexi-content-ref-26378978'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">In some cases, patients have presented with normal or only modestly elevated blood glucose (&lt;250 mg/dL), which can lead to misdiagnosis, prevent timely initiation of treatment, and negatively influence duration of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30728224','lexi-content-ref-28797889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30728224','lexi-content-ref-28797889'])">Ref</a></span>). In addition, SGLT2 inhibitor-mediated increases in urinary glucose loss may persist for several days after discontinuation which may impact duration of illness in patients who develop ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Several mechanisms have been proposed centered on increased ketone body production and reabsorption. Because SGLT2 inhibitors decrease urinary excretion of ketone bodies and decrease blood glucose in an insulin-independent manner, plasma glucose and urine ketone concentrations may be lower than what is typically expected in classic presentations of diabetic ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665','lexi-content-ref-26086329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665','lexi-content-ref-26086329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset</i>: Varied; timing is often impacted by the onset of metabolically stressful events (eg, surgery, extensive exercise, myocardial infarction, stroke, severe infections, prolonged fasting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-27082665'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients with diabetes who are insulin deficient (eg, latent autoimmune diabetes in adults, type 1 diabetes, or some patients with long-standing type 2 diabetes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082665'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Metabolically stressful events (eg, surgery, extensive exercise, myocardial infarction, stroke, severe infections, prolonged fasting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-27082665'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Presence of other risk factors that may predispose a patient to ketoacidosis (eg, pancreatic insulin deficiency, dose decreases or missed doses of insulin, caloric restriction, alcohol abuse, acute febrile illness, surgery, ketogenic diet, volume depletion, or any other extreme stress event)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of pancreatitis or pancreatic surgery</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lower limb amputations</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There are conflicting data involving the risk of lower limb amputations with sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy; canagliflozin, specifically, has been of concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-29430814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-29430814'])">Ref</a></span>). Canagliflozin was associated with almost a twofold increased risk of lower limb amputations compared to placebo in the CANVAS and CANVAS-R trials, which included patients with type 2 diabetes at high cardiovascular risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-30868176','lexi-content-ref-28605608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-30868176','lexi-content-ref-28605608'])">Ref</a></span>). Trials involving empagliflozin have not consistently shown an increased risk of lower limb amputation associated with its use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29430814','lexi-content-ref-29133344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29430814','lexi-content-ref-29133344'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32436638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32436638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; timing is often impacted by the onset of metabolically stressful events (eg, surgery, extensive exercise, myocardial infarction, stroke, severe infections, prolonged fasting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31081590','lexi-content-ref-27082665']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31081590','lexi-content-ref-27082665'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting risk factors for amputation (eg, prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers, cardiovascular disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-32843476','lexi-content-ref-28605608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-32843476','lexi-content-ref-28605608'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32843476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32843476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lack of preventative foot care</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F26016711"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dyslipidemia (4%), increased thirst (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Genitourinary fungal infection (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Genitourinary Fungal Infection table link" class="lexi-table-link" data-table-id="lexi-content-genitourinary-fungal-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-genitourinary-fungal-infection')">table 1</a>)</span><span class="table-link" style="display:none;">Genitourinary Fungal Infection</span>, increased urine output (3%), urinary tract infection (8% to 9%; incidence higher in females)<span class="lexi-table-link-container"> (<a aria-label="Urinary Tract Infection table link" class="lexi-table-link" data-table-id="lexi-content-urinary-tract-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-urinary-tract-infection')">table 2</a>)</span><span class="table-link" style="display:none;">Urinary Tract Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Genitourinary Fungal Infection" frame="border" id="lexi-content-genitourinary-fungal-infection" rules="all">
<caption style="text-align:center;">
<b>Empagliflozin: Adverse Reaction: Genitourinary Fungal Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Empagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Empagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">420</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">481</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">443</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">481</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">556</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">514</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">557</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">514</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Urinary Tract Infection" frame="border" id="lexi-content-urinary-tract-infection" rules="all">
<caption style="text-align:center;">
<b>Empagliflozin: Adverse Reaction: Urinary Tract Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Empagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Empagliflozin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">999</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">995</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">25 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">977</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">995</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased hematocrit (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Genitourinary: Phimosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (EMA 2017), urticaria (EMA 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypovolemia (higher incidence in older patients) (Kohler 2017), ketoacidosis (patients may be euglycemic; without concomitant insulin) (FDA 2015; Handelsman [AACE/ADA 2016]; Rosenstock 2018; Zinman 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (Dziadokwiec 2021, Zeidan 2020), constipation</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection with sepsis (Fisher 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (EMA 2017), hypersensitivity angiitis (To 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Necrotizing fasciitis (perineum) (Bersoff-Match 2019; FDA 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Ryan 2020), acute kidney injury (Wanner 2016; Zinman 2015), decreased estimated GFR (eGFR) (occurring early after initiation) (Wanner 2016), increased serum creatinine (Wanner 2016), pyelonephritis (Kohler 2016; Kufel 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (DeFronzo 2018)</p></div>
<div class="block coi drugH1Div" id="F25498098"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, angioedema) to empagliflozin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F26249520"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">– Euglycemic diabetic ketoacidosis: Discontinue therapy 3 to 5 days prior to surgery (Bobart 2016). Postoperatively, assess volume status, caloric intake, and need for diabetes treatment and withhold antidiabetic medication if type 2 diabetes is in remission. Ketoacidosis has been reported in patients with type 1 and type 2 diabetes on SGLT2 inhibitors. In some cases, normal or only modestly elevated blood glucose was present (&lt;250 mg/dL) (van Niekerk 2018). Risk factors include significant reduction in insulin, caloric restriction, stress of surgery, and infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Risk of intravascular volume depletion may be increased in patients ≥75 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with diabetic ketoacidosis or for glycemic control in patients with type 1 diabetes mellitus. Not for use for treatment of chronic kidney disease in patients with polycystic kidney disease, or in those who currently require or with a recent history of immunosuppressive therapy for kidney disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Use of SGLT2 inhibitors is not routinely recommended for glycemic control in hospitalized patients (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical procedures: Consider temporary discontinuation of therapy at least 3 days prior to surgery; ensure risk factors for ketoacidosis are resolved prior to reinitiating therapy.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F58523192"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Unlike adults, hypoglycemia has been reported in pediatric patients. In trials of pediatric patients ≥10 to &lt;18 years of age, the incidence of hypoglycemia (blood glucose &lt;54 mg/dL) was 19.2% in subjects treated with empagliflozin (regardless of concomitant insulin) compared to 7.5% in the placebo group. No severe hypoglycemia (ie, events requiring interventions) were reported.</p></div>
<div class="block foc drugH1Div" id="F25590210"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jardiance: 10 mg, 25 mg</p></div>
<div class="block geq drugH1Div" id="F25590208"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F25745807"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Jardiance Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $24.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $24.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871787"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jardiance: 10 mg, 25 mg</p></div>
<div class="block admp drugH1Div" id="F58523239"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer in the morning without regard to food.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical procedures:</i> Consider temporary discontinuation of therapy at least 3 days prior to surgery; ensure risk factors for ketoacidosis are resolved prior to reinitiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses: </i>Administer the missed dose as soon as possible; do not double up next dose.</p></div>
<div class="block adm drugH1Div" id="F26251490"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;">Oral: Administer once daily in the morning, with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Surgical procedures: Consider temporary discontinuation of therapy at least 3 days prior to surgery; ensure risk factors for ketoacidosis are resolved prior to reinitiating therapy.</p></div>
<div class="block sts drugH1Div" id="F26251340"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block meg drugH1Div" id="F52446082"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Jardiance: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F204629s040lbl.pdf%23page%3D47&amp;token=tKaepkkmBfQ%2BsHeGx92nF9274Q1Gq98vqowhvT7hJ5FLxtUW1RONBkKwvo3G6%2FqMlluNQ66SNCXyS1In7JE2%2FVWPaqxsxY9sxrHlMh1zlu82Vd%2BhcD6pKto91WyPjlbf&amp;TOPIC_ID=142430" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf#page=47</a></p></div>
<div class="block usep drugH1Div" id="F58523189"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjunct treatment to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (DM) (FDA approved in ages ≥10 years and adults); risk reduction of cardiovascular death in patients with type 2 DM and established cardiovascular disease (FDA approved in adults); risk reduction of cardiovascular death and hospitalization for heart failure (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F58616005"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to increased risk of urogenital infections, especially in women during the first month of use. In addition, a higher risk of euglycemic diabetic ketoacidosis has been observed in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F25590595"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, OAT1/3, OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor), UGT1A3, UGT1A8, UGT1A9, UGT2B7; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F25590592"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Insulins.  Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Empagliflozin may enhance the hypotensive effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F26251489"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy</p></div>
<div class="block rep_considerations drugH1Div" id="F56092179"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Sodium-glucose cotransporter 2 (SGLT2) inhibitors are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F26249517"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of empagliflozin in pregnancy is limited (Formoso 2018). Due to adverse effects on renal development observed in animal studies, the manufacturer does not recommend use of empagliflozin during the second and third trimesters of pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than empagliflozin are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block mopp drugH1Div" id="F58523248"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Plasma glucose, HbA<sub>1c</sub> (every 3 months; if patient is stable and meeting treatment goals, may only need twice-yearly testing [ADA 2022b]); renal function (eg, SCr, BUN) (baseline and periodically during treatment); volume status (eg, BP, hematocrit, electrolytes); monitor for genital mycotic infections and UTI; assess patients presenting with fever or malaise along with genital or perianal pain, tenderness, erythema, or swelling for necrotizing fasciitis; BP; if signs/symptoms of ketoacidosis (eg, nausea/vomiting, abdominal pain, malaise, shortness of breath), confirm diagnosis by direct measurement of blood ketones and arterial pH (measurement of serum bicarbonate or urinary ketones may not be adequate) (AACE [Handelsman 2016]).</p></div>
<div class="block rerp drugH1Div" id="F58523249"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Plasma blood glucose and HbA<sub>1c</sub> goals for patients with diabetes: Note:</b> Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and HbA<sub>1c</sub> values and to help assess glycemia for patients who receive basal/bolus or pump regimens. It is usually drawn 1 to 2 hours after starting a meal and is considered to be the "peak."</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Blood glucose:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Type 2 diabetes:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Fasting plasma glucose: 70 to 110 mg/dL (SI: 3.9 to 6.1 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:10em;">Postprandial glucose: 70 to 140 mg/dL (SI: 3.9 to 7.8 mmol/L) (ISPAD [Shah 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; lower targets may also be recommended when using insulin pumps and/or continuous glucose monitoring and during the "honeymoon" phase; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, have extensive comorbid conditions, or lack access to analog insulins, advanced insulin delivery technology, or continuous glucose monitoring (ADA 2022a; ISPAD [de Bock 2022]).</p></div>
<div class="block pha drugH1Div" id="F26251341"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">By inhibiting sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, empagliflozin reduces reabsorption of filtered glucose from the tubular lumen and lowers the renal threshold for glucose (RT<sub>G</sub>). SGLT2 is the main site of filtered glucose reabsorption; reduction of filtered glucose reabsorption and lowering of RT<sub>G</sub> result in increased urinary excretion of glucose, thereby reducing plasma glucose concentrations. Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule, which may lower both pre- and afterload of the heart and downregulate sympathetic activity.</p></div>
<div class="block phk drugH1Div" id="F26251369"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In pharmacokinetic analysis, pediatric patients 10 to &lt;18 years of age were observed to have similar empagliflozin exposure as adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Following discontinuation, urinary glucose excretion returns to baseline within ~3 days for the 10 mg and 25 mg doses.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 73.8 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 86.2%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily through glucuronidation by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 to minor metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life Elimination: 12.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to Peak: 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (54.4%; 50% as unchanged drug); feces (41.2%; majority as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51154036"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased and AUC is increased in patients with impaired renal function. In mild, moderate, and severe renal impairment and in end-stage renal disease (ESRD), AUC increased approximately 18%, 20%, 66%, and 48% respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with mild, moderate, and severe hepatic impairment, AUC increased by approximately 23%, 47%, and 75%, and C<sub>max</sub> increased by approximately 4%, 23%, and 48%, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F25576791"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adempa | Diacurimap | Emazid | Emglif | Emjard | Empa | Empaglif | Empatab | Empazin | Evania | Glifo | Glipatab | Glycenor | Jardian | Jardiance | Sinjard</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Jardianz | Jarinu</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Empabetes | Empacoza | Empaglimax | Glimpacare | Jardiance | Mellitofix</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cospiaq | Empaone | Gibtulio | Jardiance | Oboravo | Vicra</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Empaxa | Jardiance</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Jardiance | Xenglu</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Didiance | Emdiance | Emflo | Empa | Empadi | Empagle | Empagli | Empagli m | Empajin | Empance | Empaone | Emparil | Empazin | Empiance | Emplozin | Empoga | Empory | Empozin | Enpyang | Epmadi | Glinace | Idiance | Jadi m | Jadifle | Jadiplo | Jairo | Jardiance | Jardiemp | Jardiempa | Jardiflozin | Jardiheart | Pariem | Shinpoong empagliflozin | Widiance</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Empaza | Jardiance</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adrance | Diampa | Emglif | Empaa | Empalozin | Empaphage | Empator | Empoli | Empozin | Emsyn | Erli | Glempa | Jardiance | Jardy | Jemvesta | Sciampa | Truglif | Voreta | Xenglu | Yogil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Jardiance</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Jardiance | Losugby</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964868">
<a name="34964868"></a>American Diabetes Association (ADA) Professional Practice Committee, Draznin B, Aroda VR, et al. 6. Glycemic targets: standards of medical care in diabetes-2022. <i>Diabetes Care</i>. 2022a;45(suppl 1):S83-S96. doi:10.2337/dc22-S006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/34964868/pubmed" id="34964868" target="_blank">34964868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34964865">
<a name="34964865"></a>American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 14. Children and adolescents: standards of medical care in diabetes-2022. <i>Diabetes Care</i>. 2022b;45(suppl 1):S208-S231. doi:10.2337/dc22-S014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/34964865/pubmed" id="34964865" target="_blank">34964865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34449189">
<a name="34449189"></a>Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. <i>N Engl J Med</i>. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/34449189/pubmed" id="34449189" target="_blank">34449189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26982554">
<a name="26982554"></a>Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. <i>Postgrad Med</i>. 2016;128(4):409-417. doi:10.1080/00325481.2016.1167570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/26982554/pubmed" id="26982554" target="_blank">26982554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32436638">
<a name="32436638"></a>Arnott C, Huang Y, Neuen BL, et al. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. <i>Diabetes Obes Metab</i>. 2020;22(10):1753-1766. doi:10.1111/dom.14091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/32436638/pubmed" id="32436638" target="_blank">32436638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31060053">
<a name="31060053"></a>Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. <i>Ann Intern Med</i>. 2019;170(11):764-769. doi:10.7326/M19-0085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/31060053/pubmed" id="31060053" target="_blank">31060053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27699391">
<a name="27699391"></a>Bobart SA, Gleason B, Martinez N, Norris K, Williams SF. Euglycemic ketoacidosis caused by sodium-glucose cotransporter 2 inhibitors: a case report. <i>Ann Intern Med</i>. 2016;165(7):530-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27699391/pubmed" id="27699391" target="_blank">27699391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30939483">
<a name="30939483"></a>Chu C, Lu YP, Yin L, Hocher B. The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. <i>Kidney Blood Press Res</i>. 2019;44(2):149-157. doi:10.1159/000498963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30939483/pubmed" id="30939483" target="_blank">30939483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30728224">
<a name="30728224"></a>Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. <i>Diabetes Care</i>. 2019;42(6):1147-1154. doi:10.2337/dc18-2316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30728224/pubmed" id="30728224" target="_blank">30728224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30207042">
<a name="30207042"></a>Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. <i>Diabetes Obes Metab</i>. 2019;21(2):434-438. doi:10.1111/dom.13531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30207042/pubmed" id="30207042" target="_blank">30207042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD clinical practice consensus guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29949041">
<a name="29949041"></a>DeFronzo RA, Lee C, Kohler S. Safety and tolerability of combinations of empagliflozin and linagliptin in patients with type 2 diabetes: pooled data from two randomized controlled trials. <i>Adv Ther</i>. 2018;35(7):1009-1022. doi:10.1007/s12325-018-0724-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/29949041/pubmed" id="29949041" target="_blank">29949041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DeSantis.1">
<a name="DeSantis.1"></a>DeSantis A. Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28797889">
<a name="28797889"></a>Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it's not just euglycemic diabetic ketoacidosis. <i>Can J Diabetes</i>. 2017;41(5):499-503. doi:10.1016/j.jcjd.2017.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28797889/pubmed" id="28797889" target="_blank">28797889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33490300">
<a name="33490300"></a>Dziadkowiec KN, Stawinski PM, Proenza J. Empagliflozin-associated pancreatitis: a consideration for SGLT2 inhibitors. <i>ACG Case Rep J</i>. 2021;8(1):e00530. doi:10.14309/crj.0000000000000530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/33490300/pubmed" id="33490300" target="_blank">33490300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36507634">
<a name="36507634"></a>ElSayed NA, Aleppo G, Aroda VR, et al; American Diabetes Association (ADA). 11. Chronic kidney disease and risk management: standards of care in diabetes-2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S191-S202. doi:10.2337/dc23-S011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/36507634/pubmed" id="36507634" target="_blank">36507634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36331190">
<a name="36331190"></a>EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. <i>N Engl J Med</i>. Published online November 4, 2022. doi:10.1056/NEJMoa2204233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/36331190/pubmed" id="36331190" target="_blank">36331190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMT.2017">
<a name="EMT.2017"></a>European Medicines Agency (EMA). Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s). https://www.ema.europa.eu/en/documents/scientific-conclusion/jardiance-h-c-psusa-00010388-201610-epar-scientific-conclusions-grounds-variation-terms-marketing_en.pdf. Published May 18, 2017. Accessed March 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). Food and Drug Administration website. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine</a>. Published May 26, 2017. Accessed October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2015">
<a name="FDA.2015"></a>FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious</a>. Published December 4, 2015. Accessed August 25, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2016">
<a name="FDA.2016"></a>FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin</a>. Published June 17, 2016. Accessed August 25, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2018">
<a name="FDA.2018"></a>FDA Drug Safety Communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes</a>. Published September 7, 2018. Accessed August 25, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Food and Drug Administration website. <a href="https://www.fda.gov/media/92185/download" target="_blank">https://www.fda.gov/media/92185/download</a> Accessed May 15, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32383792">
<a name="32383792"></a>Fisher A, Fralick M, Filion KB, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study. <i>Diabetes Obes Metab</i>. 2020;22(9):1648-1658. doi:10.1111/dom.14082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/32383792/pubmed" id="32383792" target="_blank">32383792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31081590">
<a name="31081590"></a>Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. <i>Diabetes Obes Metab</i>. 2019;21(suppl 2):34-42. doi:10.1111/dom.13611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/31081590/pubmed" id="31081590" target="_blank">31081590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Formoso.1">
<a name="Formoso.1"></a>Formoso G, Ginestra F, Di Dalmazi G, Consoli A. Empagliflozin, metformin and insulin degludec, during pregnancy: a case report. <i>Acta Diabetol</i>. 2018;55(7):759-761.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32843476">
<a name="32843476"></a>Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. <i>BMJ</i>. 2020;370:m2812. doi:10.1136/bmj.m2812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/32843476/pubmed" id="32843476" target="_blank">32843476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24529566">
<a name="24529566"></a>Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. <i>Diabetes Res Clin Pract</i>. 2014;103(3):373-381. doi:10.1016/j.diabres.2013.12.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/24529566/pubmed" id="24529566" target="_blank">24529566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31050116">
<a name="31050116"></a>Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. <i>Diabetes Obes Metab</i>. 2019;21(8):1996-2000. doi:10.1111/dom.13754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/31050116/pubmed" id="31050116" target="_blank">31050116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27847389">
<a name="27847389"></a>Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. <i>Nat Rev Nephrol</i>. 2016;12(12):711-712. doi:10.1038/nrneph.2016.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27847389/pubmed" id="27847389" target="_blank">27847389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27082665">
<a name="27082665"></a>Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. <i>Endocr Pract</i>. 2016;22(6):753-762. doi:10.4158/EP161292.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27082665/pubmed" id="27082665" target="_blank">27082665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23963895">
<a name="23963895"></a>Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. <i>Diabetes Care</i>. 2013;36(11):3396-3404. doi:10.2337/dc12-2673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/23963895/pubmed" id="23963895" target="_blank">23963895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133344">
<a name="29133344"></a>Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. <i>Diabetes Care</i>. 2018;41(1):e4-e5. doi:10.2337/dc17-1551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/29133344/pubmed" id="29133344" target="_blank">29133344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jardiance.1">
<a name="Jardiance.1"></a>Jardiance (empagliflozin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jardiance.3">
<a name="Jardiance.3"></a>Jardiance (empagliflozin) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; January 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29430814">
<a name="29430814"></a>Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? <i>Diabetes Obes Metab</i>. 2018;20(6):1531-1534. doi:10.1111/dom.13255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/29430814/pubmed" id="29430814" target="_blank">29430814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int. </i>2020;98(4S):S1-S115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27085585">
<a name="27085585"></a>Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. <i>Clin Ther</i>. 2016;38(6):1299-1313. doi:10.1016/j.clinthera.2016.03.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27085585/pubmed" id="27085585" target="_blank">27085585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631216">
<a name="28631216"></a>Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. <i>Adv Ther</i>. 2017;34(7):1707-1726. doi:10.1007/s12325-017-0573-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28631216/pubmed" id="28631216" target="_blank">28631216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27876693">
<a name="27876693"></a>Kufel WD, Scrimenti A, Steele JM. A case of septic shock due to Serratia marcescens pyelonephritis and bacteremia in a patient receiving empagliflozin. <i>J Pharm Pract</i>. 2017;30(6):672-675. doi:10.1177/0897190016679760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27876693/pubmed" id="27876693" target="_blank">27876693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36738751">
<a name="36738751"></a>Laffel LM, Danne T, Klingensmith GJ, et al. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. <i>Lancet Diabetes Endocrinol</i>. 2023;11(3):169-181. doi:10.1016/S2213-8587(22)00387-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/36738751/pubmed" id="36738751" target="_blank">36738751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27862830">
<a name="27862830"></a>Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2017;19(3):348-355. doi:10.1111/dom.12825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27862830/pubmed" id="27862830" target="_blank">27862830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23859534">
<a name="23859534"></a>Macha S, Rose P, Matteus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. <i>Diabetes Obes Metab</i>. 2014;16(2):118-123. doi:10.1111/dom.12183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/23859534/pubmed" id="23859534" target="_blank">23859534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30868176">
<a name="30868176"></a>Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i>. 2019;62(6):926-938. doi:10.1007/s00125-019-4839-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30868176/pubmed" id="30868176" target="_blank">30868176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28546454">
<a name="28546454"></a>Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. <i>J Am Heart Assoc</i>. 2017;6(6):e004007. doi:10.1161/JAHA.116.004007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28546454/pubmed" id="28546454" target="_blank">28546454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741440">
<a name="31741440"></a>McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. <i>Am J Cardiol</i>. 2019;124(suppl 1):S45-S52. doi:10.1016/j.amjcard.2019.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/31741440/pubmed" id="31741440" target="_blank">31741440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures -2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi:10.1097/SLA.0b013e3182774522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28605608">
<a name="28605608"></a>Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med</i>. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28605608/pubmed" id="28605608" target="_blank">28605608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495651">
<a name="31495651"></a>Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes Endocrinol</i>. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/31495651/pubmed" id="31495651" target="_blank">31495651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888425">
<a name="28888425"></a>Nichols GA, Brodovicz KG, Kimes TM, Déruaz-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. <i>J Diabetes Complications</i>. 2017;31(11):1587-1591. doi:10.1016/j.jdiacomp.2017.07.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28888425/pubmed" id="28888425" target="_blank">28888425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9734886">
<a name="9734886"></a>Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. <i>Lancet</i>. 1998;351(9117):1693-1697. doi:10.1016/S0140-6736(97)09137-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/9734886/pubmed" id="9734886" target="_blank">9734886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23748505">
<a name="23748505"></a>Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. <i>Postgrad Med</i>. 2013;125(3):33-46. doi:10.3810/pgm.2013.05.2650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/23748505/pubmed" id="23748505" target="_blank">23748505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26041448">
<a name="26041448"></a>O'Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. <i>Am J Physiol Renal Physiol</i>. 2015;309(3):F227-F234. doi:10.1152/ajprenal.00689.2014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/26041448/pubmed" id="26041448" target="_blank">26041448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32865377">
<a name="32865377"></a>Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. <i>N Engl J Med</i>. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/32865377/pubmed" id="32865377" target="_blank">32865377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V, Badve SV, Bakris GL. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenberg.1">
<a name="Rosenberg.1"></a>Rosenberg M. Overview of the management of chronic kidney disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30287422">
<a name="30287422"></a>Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. <i>Diabetes Care</i>. 2018;41(12):2560-2569. doi:10.2337/dc18-1749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30287422/pubmed" id="30287422" target="_blank">30287422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440590">
<a name="28440590"></a>Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis. <i>Diabetes Metab Res Rev</i>. 2017;33(6). doi: 10.1002/dmrr.2903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28440590/pubmed" id="28440590" target="_blank">28440590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33777384">
<a name="33777384"></a>Ryan R, Choo S, Willows J, Walker J, Prasad K, Tez D. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. <i>Clin Kidney J</i>. 2020;14(3):1020-1022. doi:10.1093/ckj/sfaa033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/33777384/pubmed" id="33777384" target="_blank">33777384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16644645">
<a name="16644645"></a>Schaefer-Graf UM, Hartmann R, Pawliczak J, et al. Association of breast-feeding and early childhood overweight in children from mothers with gestational diabetes mellitus. <i>Diabetes Care</i>. 2006;29(5):1105-1107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/16644645/pubmed" id="16644645" target="_blank">16644645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27407013">
<a name="27407013"></a>Tang HL, Li DD, Zhang JJ, et al. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2016;18(12):1199-1206. doi:10.1111/dom.12742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27407013/pubmed" id="27407013" target="_blank">27407013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28240446">
<a name="28240446"></a>Tang H, Li D, Zhang J, et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes Obes Metab</i>. 2017;19(8):1106-1115. doi:10.1111/dom.12917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28240446/pubmed" id="28240446" target="_blank">28240446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26086329">
<a name="26086329"></a>Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2849-2852. doi:10.1210/jc.2015-1884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/26086329/pubmed" id="26086329" target="_blank">26086329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25271206">
<a name="25271206"></a>Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. <i>Diabetes Care</i>. 2015;38(3):420-428. doi:10.2337/dc14-1096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/25271206/pubmed" id="25271206" target="_blank">25271206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29457486">
<a name="29457486"></a>To D, Bradshaw S, Lipson J. Case report of empagliflozin-induced cutaneous polyarteritis nodosa. <i>J Cutan Med Surg</i>. 2018;22(5):516-518. doi:10.1177/1203475418760457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/29457486/pubmed" id="29457486" target="_blank">29457486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30131409">
<a name="30131409"></a>van Niekerk C, Wallace J, Takata M, Yu R. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin. <i>BMJ Case Rep</i>. Published online August 20, 2018. doi:10.1136/bcr-2017-221527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30131409/pubmed" id="30131409" target="_blank">30131409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27299675">
<a name="27299675"></a>Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. <i>N Engl J Med</i>. 2016;375(4):323-334. doi:10.1056/NEJMoa1515920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/27299675/pubmed" id="27299675" target="_blank">27299675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28904068">
<a name="28904068"></a>Wanner C, Lachin JM, Inzucchi SE, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. <i>Circulation</i>. 2018;137(2):119-129. doi:10.1161/CIRCULATIONAHA.117.028268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/28904068/pubmed" id="28904068" target="_blank">28904068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Management of persistent hyperglycemia in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30415602">
<a name="30415602"></a>Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med</i>. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30415602/pubmed" id="30415602" target="_blank">30415602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33520523">
<a name="33520523"></a>Zeidan BS Jr, Boadu C, Hernandez A, Frunzi J, Adetula I. Adverse side effects: empagliflozin-related acute pancreatitis case report. <i>Cureus</i>. 2020;12(12):e12325. doi:10.7759/cureus.12325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/33520523/pubmed" id="33520523" target="_blank">33520523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30424892">
<a name="30424892"></a>Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i>. 2019;393(10166):31-39. doi:10.1016/S0140-6736(18)32590-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/30424892/pubmed" id="30424892" target="_blank">30424892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26378978">
<a name="26378978"></a>Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med</i>. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/empagliflozin-pediatric-drug-information/abstract-text/26378978/pubmed" id="26378978" target="_blank">26378978</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 142430 Version 18.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
